JDQ443
Phase 2ActiveDevelopment Stage
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Dec 6, 2022 → Dec 31, 2026
About JDQ443
JDQ443 is a phase 2 stage product being developed by Novartis for Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. The current trial status is active. This product is registered under clinical trial identifier NCT05445843. Target conditions include Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation were approved
Hype Score Breakdown
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05999357 | Phase 2 | Withdrawn |
| NCT05714891 | Phase 2 | Active |
| NCT05445843 | Phase 2 | Active |
| NCT05329623 | Phase 1 | Completed |
Competing Products
20 competing products in Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation